OPDIVO®
(nivolumab)

Patient Alert Card

Evaluated by Norwegian Health Authority: Nov 2020
Local Approval Number: ONC-NO-2300014

Bristol Myers Squibb™

Important Information for Patients

Please carry this card with you at all times to inform healthcare professionals that you are receiving treatment with OPDIVO® or OPDIVO® in combination with YERVOY® (ipilimumab).

If you have any signs or symptoms, tell your doctor right away.

IMPORTANT

OPDIVO® treatment may increase the risk of serious or even life-threatening immune-related side-effects, which may affect different parts of the body, for example:

Chest (heart and lungs): breathing difficulties, cough, wheeze, chest pain, irregular heartbeat, palpitations (increased awareness of your heartbeat)

Gut (stomach and bowels): diarrhoea (watery, loose or soft stools), blood or mucus in stools, dark-coloured stools, pain or tenderness in your stomach or abdominal area

Liver: eye or skin yellowing (jaundice), pain on the right side of your stomach area

Kidneys: change in amount and/or frequency of urine

Skin: rash, itching, blisters and/or peeling of the skin (possibly fatal), ulcers, dry skin, skin nodules

Hormone-producing glands (including Diabetes): headaches, blurry or double vision, fatigue (tiredness), weight changes, behavioural changes (e.g. lower sex drive, irritability or forgetfulness), excessive thirst, increased appetite with weight loss, weakness, drowsiness, depression, irritability, feeling unwell, change in amount and/or frequency of urine

Other: weakness, fatigue (tiredness), decreased appetite, nausea, vomiting, tingling or numbness in arms and legs, difficulty walking, fever, swollen lymph nodes, headache, seizures, stiff neck,

confusion, drowsiness, muscle pain, stiffness, dark urine, eye pain or redness, blurry vision, or other vision problems

Version 10, Nov 2020

IMPORTANT

- Tell your doctor of previous medical conditions, including if you have had a stem cell transplant that used donor stem cells (allogeneic).
- Early assessment and management of side-effects by your doctor reduces the likelihood that treatment with OPDIVO® or OPDIVO® in combination with YERVOY® will need to be temporarily or permanently stopped.
- **DO NOT** try to treat these symptoms yourself.
- Signs and symptoms that may appear mild can quickly worsen if left untreated.
- Signs and symptoms may be delayed and may occur weeks to months after your last injection.

For more information, read the OPDIVO® Package Leaflet via **www.felleskatalogen.no** or call Bristol Myers Squibb Medical information (Norway) on +47 23 12 06 37.

My Doctor's Contact Information (who prescribed OPDIVO® or OPDIVO® in combination with YERVOY®)

Name of Doctor:

.....

Office Phone:

.....

Out-of-Hours Phone:

.....

My Contact Information

My Name:

.....

My Phone Number:

.....

Emergency Contact (name and phone number):

.....

IMPORTANT Information for Healthcare Professionals

- This patient is treated with **OPDIVO®** or **OPDIVO® in combination with YERVOY®.**
- Immune-related adverse reactions (irARs) may appear at any time during treatment or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimise life-threatening complications.
- Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific irARs.
- Healthcare professionals should refer to the OPDIVO® Summary of Product Characteristics (SmPC) via **www.felleskatalogen.no**, **www.legemiddelsok.no** or contact Bristol Myers Squibb

  Medical Information (Norway) on + 47 23 12 06 37 for more information. The patient card is also available for downloading at **www.felleskatalogen.no**.

The healthcare professional treating this patient with OPDIVO® or OPDIVO® in combination with YERVOY® should complete the 'My Doctor's Contact Information' section of this Patient Alert Card.

Version 10, Nov 2020